Bo Ahrén
91 – 100 of 398
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Pronounced Reduction Of Postprandial Glucagon By Lixisenatide: A Meta-Analysis Of Randomized Clinical Trials.
- Contribution to journal › Article
-
Mark
Fibroblast Growth Factor 21 (FGF21) and Glucagon Like-Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor Deficient Mice.
- Contribution to journal › Article
-
Mark
The neuro-incretin concept.
- Contribution to journal › Debate/Note/Editorial
-
Mark
GLP-1 released to the mesenteric lymph duct in mice: Effects of glucose and fat.
- Contribution to journal › Article
-
Mark
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
- Contribution to journal › Article
-
Mark
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
- Contribution to journal › Article
-
Mark
Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
- Contribution to journal › Article
-
Mark
Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial
- Contribution to journal › Article
-
Mark
The mind and the belly: a glance at how the nervous system directs metabolism
- Contribution to journal › Debate/Note/Editorial
-
Mark
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.
- Contribution to journal › Article
